Related Experiment Videos
Posttransfusion non-A, non-B hepatitis after cardiac surgery: a prospective study
Vox Sanguinis
|January 1, 1983
Summary
A prospective study found that 8% of cardiac surgery patients receiving HBsAg-negative blood developed non-A, non-B hepatitis. Higher blood product transfusion volumes correlated with increased hepatitis risk, highlighting posttransfusion hepatitis as a significant medical concern.
Area of Science:
- Hepatology
- Transfusion Medicine
- Infectious Diseases
Background:
- Posttransfusion hepatitis is a significant concern in patients undergoing cardiac surgery.
- Hepatitis B surface antigen (HBsAg)-negative blood transfusions were administered to assess non-A, non-B hepatitis transmission.
Observation:
- A prospective study involved 50 cardiac surgery patients who received HBsAg-negative blood.
- Four patients (8%) developed acute non-A, non-B hepatitis.
- Hepatitis patients received significantly more blood products than non-hepatitis patients.
Findings:
- The incubation period for non-A, non-B hepatitis ranged from 4 to 13 weeks.
- Three asymptomatic patients had peak alanine aminotransferase (ALT) levels between 320-497 U/L.
- One symptomatic patient presented with jaundice and a peak ALT of 3,400 U/L.
- One patient showed elevated ALT levels after 21 weeks; three recovered within 7-10 weeks.
Implications:
- Non-A, non-B posttransfusion hepatitis in Israel presents a clinical challenge comparable to that in the USA.
- The clinical spectrum of posttransfusion hepatitis varies from asymptomatic to symptomatic and prolonged courses.
- This study underscores the importance of monitoring and managing non-A, non-B hepatitis in transfusion recipients, particularly post-cardiac surgery.